Genprex, Inc. today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company’s co-founder and previous Chairman Rodney Varner.
Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company’s co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman, Mr. Moreno Toscano has served on Genprex’s Board of Directors since March 2020. Since April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc, the US subsidiary of LFB Group, a global integrated biopharmaceutical company, and he has more than 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations and general management. Mr. Moreno Toscano’s appointment follows the recent appointment of Ryan Confer to serve as Genprex’s President and Chief Executive Officer. Mr. Confer was also appointed to Genprex’s Board of Directors. Mr. Moreno Toscano commented: “On behalf of Genprex’s Board of Directors, we wish to express our support for Ryan as Genprex’s new President and Chief Executive Officer. We have worked closely with Ryan over the last several years, and we have seen his robust leadership skills and exceptional operational organization. He has strengthened the company’s operational and financial foundation, bolstered the company’s talent and culture, added value in every company department and has continuously advanced the company’s strategies year after year. I look forward to working alongside Ryan and our other fellow directors in my role as Chairman in what I believe will be a transformational time for Genprex.” About Genprex, Inc. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking Statements Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the appointment and transition of management personnel and other succession plan-related activities; Genprex’s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status, including Genprex’s ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex’s commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex’s intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. GNPX Investor Relations GNPX Media Contact View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-announces-the-appointment-of-jose-a-moreno-toscano-as-chairman-of-the-board-of-directors-302142996.html SOURCE Genprex, Inc. | ||
Company Codes: NASDAQ-NMS:GNPX |